Your session is about to expire
← Back to Search
Unknown
NBI-827104 for Epileptic Encephalopathy
Phase 2
Waitlist Available
Research Sponsored by Neurocrine Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 6 and week 12
Summary
This trial is testing a medication called NBI-827104 to see if it can help children with a severe type of epilepsy that affects their brain activity during sleep by reducing abnormal brain signals.
Eligible Conditions
- Epileptic Encephalopathy
- Epileptic Spasms
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 6 and week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 6 and week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Caregiver Global Impression of Change (GI-C) and Clinical Global Impression of Change (CGI-C) scores.
Clinical Global Impression of Severity (CGI-S) scores.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NBI-827104Experimental Treatment1 Intervention
NBI-827104 administered orally for 13 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered orally for 13 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NBI-827104
2021
Completed Phase 2
~60
Find a Location
Who is running the clinical trial?
Neurocrine BiosciencesLead Sponsor
75 Previous Clinical Trials
6,699 Total Patients Enrolled
1 Trials studying Epileptic Encephalopathy
24 Patients Enrolled for Epileptic Encephalopathy
Clinical Development LeadStudy DirectorNeurocrine Biosciences
24 Previous Clinical Trials
2,550 Total Patients Enrolled
1 Trials studying Epileptic Encephalopathy
24 Patients Enrolled for Epileptic Encephalopathy
Share this study with friends
Copy Link
Messenger